Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.

Area of Science:

• Immunology
• Endocrinology
• Bone Biology

Background:

• Postmenopausal osteoporosis results from estrogen deficiency, leading to bone loss and increased fracture risk.
• Estrogen deficiency alters immune status, promoting a chronic inflammatory state that contributes to bone destruction.
• Immune cells interact with bone cells (osteoblasts and osteoclasts) via direct contact or paracrine signaling, influencing bone remodeling.

Purpose of the Study:

• To elucidate the role of immune cell alterations in the pathogenesis of postmenopausal osteoporosis.
• To understand how various immune cell subtypes contribute to bone loss and impaired healing under estrogen-deficient conditions.

Main Methods:

• Review of existing literature on immune cell interactions and their impact on bone metabolism in postmenopausal osteoporosis.
• Analysis of cytokine expression and immune cell profiles associated with estrogen deficiency and bone disease.

Main Results:

• T lymphocytes (Th17) and B lymphocytes contribute to osteoclastogenesis and bone loss via cytokines like TNFα, IL-17, and RANKL.
• Macrophages, neutrophils, and mast cells also play significant roles, with altered polarization and mediator release (e.g., IL-6, RANKL) exacerbating bone destruction.
• Estrogen deficiency impairs bone fracture healing due to pro-inflammatory cytokines like IL-6 and Midkine.

Conclusions:

• Immune cell dysregulation is a critical factor in postmenopausal osteoporosis pathogenesis, acting alongside estrogen deficiency.
• Targeting specific immune pathways may offer novel therapeutic strategies for managing postmenopausal osteoporosis and improving fracture healing.